Jasper Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De winst van Jasper Therapeutics zal naar verwachting dalen met 15.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 69.6% per jaar. De winst per aandeel zal naar verwachting afnemen met 2.7% per jaar.

Belangrijke informatie

-15.8%

Groei van de winst

-2.7%

Groei van de winst per aandeel

Biotechs winstgroei	27.6%
Inkomstengroei	69.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23

Winst- en omzetgroeiprognoses

NasdaqCM:JSPR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2	-97	-82	-73	7
12/31/2025	5	-75	-67	-63	9
12/31/2024	N/A	-62	-57	-56	10
6/30/2024	N/A	-62	-56	-56	N/A
3/31/2024	N/A	-64	-58	-57	N/A
12/31/2023	N/A	-64	-52	-52	N/A
9/30/2023	N/A	-61	-48	-48	N/A
6/30/2023	N/A	-55	-46	-46	N/A
3/31/2023	N/A	-50	-43	-42	N/A
12/31/2022	N/A	-38	-46	-46	N/A
9/30/2022	N/A	-34	-49	-48	N/A
6/30/2022	N/A	-25	-47	-45	N/A
3/31/2022	N/A	-23	-43	-42	N/A
12/31/2021	N/A	-31	-36	-34	N/A
9/30/2021	N/A	-32	-26	-24	N/A
6/30/2021	N/A	-39	-27	-25	N/A
3/31/2021	N/A	-40	-24	-23	N/A
12/31/2020	N/A	-32	-18	-18	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat JSPR de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat JSPR de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat JSPR de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van JSPR ( 69.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van JSPR ( 69.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van JSPR naar verwachting over 3 jaar hoog zal zijn

Jasper Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.7% to US$69.13

Price target decreased by 11% to US$61.25

Price target increased by 9.8% to US$6.88

Price target increased by 11% to US$5.97

Price target decreased by 9.0% to US$7.10

Price target decreased to US$7.80

Recent updates

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80

High number of new directors

Price target decreased to US$12.00

Jasper Therapeutics Receives Written Notice from Nasdaq

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, in the Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Price target decreased to US$12.25

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Non-Executive Chairperson of the Board notifies of intention to sell stock

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. Announces Development of Novel Curative Therapies Based on the Biology of the Hematopoietic Stem Cell

Jasper Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Jasper Therapeutics, Inc. Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

No independent directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven